Assessing the Impact of Ultra-Low Cut Points in Immunogenicity Assays

Assessing the Impact of Ultra-Low Cut Points in Immunogenicity Assays

December 2, 2024 BioData Solutions

Ultra-low cut points for your Anti-Drug Antibody assays can sometimes be concerning. In partnership with ICON plc, we studied a few different datasets. Download the poster to learn about our observations.

App Notes

Cross-Validation of Statistical Workflow for Cut Point Calculation using Red Thread (Python) Vs R

September 17, 2024

Comparing Cut Points Between Statistical Software Stata and R Using Random Effects Model

September 17, 2024

Case Studies

Simplifying Bioanalytical Review Using Advanced Computational Techniques

September 17, 2024

Posters

Development and Optimization of a Quantitative Assay for an Investigational Anti-Malarial Monoclonal Antibody Drug Candidate in Human Whole Blood Using Volumetric Absorptive Microsampling (VAMS)

April 15, 2025

Assessing the Impact of Ultra-Low Cut Points in Immunogenicity Assays

December 2, 2024

Singlet Analysis Yields Equivalent Results as Duplicate Analysis in Preclinical Immunogenicity Assessment

September 17, 2024

Can Automation Improve Compliance, Consistency, & Efficiency for CGTP Data Analysis

September 17, 2024

White Papers

Artificial Intelligence increases efficiencies and reduces bias for bioanalytical pharmacokinetic studies and anti-drug antibody statistical determinations

September 17, 2024